Brown Advisory Inc. Reduces Stock Position in AbbVie Inc. $ABBV

Brown Advisory Inc. reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 0.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 874,943 shares of the company’s stock after selling 7,722 shares during the period. Brown Advisory Inc.’s holdings in AbbVie were worth $199,916,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Chelsea Counsel Co. purchased a new stake in shares of AbbVie during the third quarter worth about $26,000. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie during the fourth quarter worth about $28,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie during the fourth quarter worth about $29,000. IFC & Insurance Marketing Inc. purchased a new stake in shares of AbbVie during the fourth quarter worth about $31,000. Finally, Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie during the third quarter worth about $31,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Analysts Set New Price Targets

Several analysts have commented on the stock. Piper Sandler raised their price objective on shares of AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Cantor Fitzgerald restated an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a report on Thursday, April 30th. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, June 7th. Royal Bank Of Canada assumed coverage on shares of AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective for the company. Finally, Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective for the company in a report on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average price target of $253.43.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $227.54 on Friday. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81. The company has a 50 day simple moving average of $211.05 and a two-hundred day simple moving average of $219.07. The company has a market capitalization of $402.02 billion, a price-to-earnings ratio of 112.09, a P/E/G ratio of 0.70 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter last year, the firm earned $2.46 earnings per share. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, analysts forecast that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.